OncoMatch/Clinical Trials/NCT05917145
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
Is NCT05917145 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies WSD0628 for glioblastoma.
Treatment: WSD0628 — The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Biomarker criteria
Allowed: IDH1 mutation
Grade 3 or 4 IDH1/2 mutant astrocytoma (2021 WHO classification)
Allowed: IDH2 mutation
Grade 3 or 4 IDH1/2 mutant astrocytoma (2021 WHO classification)
Allowed: IDH1 wild-type
Glioblastoma, IDH-wildtype
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radiation therapy — glioma
Disease progression after previous treatment for glioma with radiation and chemotherapy
Must have received: chemotherapy — glioma
Disease progression after previous treatment for glioma with radiation and chemotherapy
Cannot have received: radiation therapy
Radiation therapy <= 26 weeks prior to registration (including gamma tiles)
Cannot have received: chemotherapy
Chemotherapy, immunotherapy, or any investigational drug <= four weeks prior to registration
Cannot have received: immunotherapy
Chemotherapy, immunotherapy, or any investigational drug <= four weeks prior to registration
Cannot have received: investigational drug
Chemotherapy, immunotherapy, or any investigational drug <= four weeks prior to registration
Cannot have received: alkylating agent (carmustine, lomustine)
carmustine (BCNU) or lomustine (CCNU) <= six weeks prior to registration
Lab requirements
Blood counts
Hemoglobin ≥9.0 g/dL; Leukocytes ≥3.0 x 10^9/L; ANC ≥1500/mm3 or 1.5 x 10^9/L; Platelet count ≥100,000/mm3 or 100 x 10^9/L
Kidney function
Calculated creatinine clearance ≥45 ml/min using Cockcroft-Gault formula
Liver function
Total bilirubin ≤1.5 x ULN and <3 mg/dL for patients with Gilbert's disease; ALT and AST ≤3 x ULN
Cardiac function
PT/INR/aPTT ≤1.5 x ULN OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy
The following laboratory values obtained ≤15 days prior to registration: Hemoglobin ≥9.0 g/dL; Leukocytes ≥3.0 x 10^9/L; ANC ≥1500/mm3 or 1.5 x 10^9/L; Platelet count ≥100,000/mm3 or 100 x 10^9/L; Total bilirubin ≤1.5 x ULN and <3 mg/dL for patients with Gilbert's disease; ALT and AST ≤3 x ULN; PT/INR/aPTT ≤1.5 x ULN OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy; Calculated creatinine clearance ≥45 ml/min using Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05917145 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, chemotherapy, immunotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages